Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy
Author:
Affiliation:
1. Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA
Funder
CTI BioPharma
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1832674
Reference10 articles.
1. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
2. Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
3. Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
4. CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells
5. Amino acid limitation regulatesCHOPexpression through a specific pathway independent of the unfolded protein response
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Aminopeptidase N as a potential drug target;European Pharmaceutical Journal;2023-12-01
2. Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells;Cancer Drug Resistance;2023
3. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?;Cancers;2022-01-26
4. Revealing stakeholders' motivation and influence in crane conservation in the Republic of Korea: Net‐Map as a tool;Conservation Science and Practice;2021-02-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3